Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.

Koduru S, Wong E, Strowig T, Sundaram R, Zhang L, Strout MP, Flavell RA, Schatz DG, Dhodapkar KM, Dhodapkar MV.

Blood. 2012 Mar 8;119(10):2302-9. doi: 10.1182/blood-2011-08-376236. Epub 2012 Jan 10.

2.

Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling.

Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watashi K, Shimotohno K, Honjo T, Chiba T.

Oncogene. 2007 Aug 16;26(38):5587-95. Epub 2007 Apr 2.

PMID:
17404578
3.

Activation-induced cytidine deaminase-initiated off-target DNA breaks are detected and resolved during S phase.

Hasham MG, Snow KJ, Donghia NM, Branca JA, Lessard MD, Stavnezer J, Shopland LS, Mills KD.

J Immunol. 2012 Sep 1;189(5):2374-82. doi: 10.4049/jimmunol.1200414. Epub 2012 Jul 23.

4.
5.

Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma.

Kim JH, Kim WS, Park C.

Leuk Lymphoma. 2013 Sep;54(9):2035-40. doi: 10.3109/10428194.2013.769218. Epub 2013 Feb 28.

PMID:
23363221
6.

Decoupling of normal CD40/interleukin-4 immunoglobulin heavy chain switch signal leads to genomic instability in SGH-MM5 and RPMI 8226 multiple myeloma cell lines.

Hwang WY, Gullo CA, Shen J, Poh CK, Tham SC, Cow G, Au M, Chan EW, Teoh G.

Leukemia. 2006 Apr;20(4):715-23.

PMID:
16453006
7.

Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination.

Hasham MG, Donghia NM, Coffey E, Maynard J, Snow KJ, Ames J, Wilpan RY, He Y, King BL, Mills KD.

Nat Immunol. 2010 Sep;11(9):820-6. doi: 10.1038/ni.1909. Epub 2010 Jul 25.

8.

Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.

Tucci M, Ciavarella S, Strippoli S, Brunetti O, Dammacco F, Silvestris F.

Exp Hematol. 2011 Jul;39(7):773-83.e1. doi: 10.1016/j.exphem.2011.04.006. Epub 2011 Apr 25.

PMID:
21569821
9.

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.

Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N.

Exp Hematol. 2013 Apr;41(4):387-97.e1. doi: 10.1016/j.exphem.2012.11.005. Epub 2012 Nov 23.

PMID:
23178378
10.

Enhancement of clonogenicity of human multiple myeloma by dendritic cells.

Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R, Jagannath S, Dhodapkar MV.

J Exp Med. 2006 Aug 7;203(8):1859-65. Epub 2006 Jul 31.

11.

Role of activation-induced cytidine deaminase in inflammation-associated cancer development.

Marusawa H, Takai A, Chiba T.

Adv Immunol. 2011;111:109-41. doi: 10.1016/B978-0-12-385991-4.00003-9. Review.

PMID:
21970953
12.

Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.

Kukreja A, Radfar S, Sun BH, Insogna K, Dhodapkar MV.

Blood. 2009 Oct 15;114(16):3413-21. doi: 10.1182/blood-2009-03-211920. Epub 2009 Aug 6.

13.

Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis.

Kou T, Marusawa H, Kinoshita K, Endo Y, Okazaki IM, Ueda Y, Kodama Y, Haga H, Ikai I, Chiba T.

Int J Cancer. 2007 Feb 1;120(3):469-76.

14.

Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression.

Morisawa T, Marusawa H, Ueda Y, Iwai A, Okazaki IM, Honjo T, Chiba T.

Int J Cancer. 2008 Dec 15;123(12):2735-40. doi: 10.1002/ijc.23853.

15.

The double-edged sword of activation-induced cytidine deaminase.

Wu X, Geraldes P, Platt JL, Cascalho M.

J Immunol. 2005 Jan 15;174(2):934-41.

16.

Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Yang Y, Ren Y, Ramani VC, Nan L, Suva LJ, Sanderson RD.

Cancer Res. 2010 Nov 1;70(21):8329-38. doi: 10.1158/0008-5472.CAN-10-2179. Epub 2010 Oct 26.

17.

Repression of human activation induced cytidine deaminase by miR-93 and miR-155.

Borchert GM, Holton NW, Larson ED.

BMC Cancer. 2011 Aug 10;11:347. doi: 10.1186/1471-2407-11-347.

18.
19.

Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.

Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC.

Clin Cancer Res. 2012 Sep 1;18(17):4669-81. doi: 10.1158/1078-0432.CCR-12-0779. Epub 2012 Jul 17.

Supplemental Content

Support Center